Stock-Based Compensation: The estimated market value of stock options, warrants and other stock-based compensation given to employees and/or vendors.
Candel Therapeutics, Inc. (CADL) had Stock-Based Compensation of $4.31M for the most recently reported fiscal quarter, ending 2026-06-30.
| Income Statement Financials | |
-- |
|
$-38.91M |
|
-- |
|
-- |
|
$26.75M |
|
$-26.75M |
|
$-12.16M |
|
$-38.91M |
|
$-38.91M |
|
$-38.91M |
|
$-38.91M |
|
$-38.91M |
|
$-38.91M |
|
$-26.75M |
|
$-26.57M |
|
74.13M |
|
74.13M |
|
$-0.52 |
|
$-0.52 |
|
| Balance Sheet Financials | |
$204.16M |
|
$2.00M |
|
$3.99M |
|
$208.15M |
|
$12.69M |
|
$47.83M |
|
$69.33M |
|
$82.02M |
|
$126.13M |
|
$126.13M |
|
$126.13M |
|
76.12M |
|
| Cash Flow Statement Financials | |
$-35.22M |
|
$-0.74M |
|
$117.80M |
|
$120.15M |
|
$201.98M |
|
$81.83M |
|
|
Stock-Based Compensation |
$4.31M |
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
16.09 |
|
-- |
|
-- |
|
0.28 |
|
0.38 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-35.96M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-30.85% |
|
-30.85% |
|
-18.69% |
|
-22.36% |
|
$1.66 |
|
$-0.49 |
|
$-0.48 |
|